Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced it has received clinical trial...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has submitted a new indication approval...
Ab&B Bio-Tech Co., Ltd. (HKG: 2627) announced it has received clinical trial approval from China’s...
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced it has received clinical clearance...
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced the inauguration of its Hong...
Harbour BioMed (HKG: 2142) announced it has received clearance from the U.S. Food and Drug...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced a strategic partnership with...
Johnson & Johnson (J&J, NYSE: JNJ) announced the termination of development programs for JNJ-9530, a...
Harbour BioMed (HKG: 2142) announced its participation in a $165 million cross financing round for...
Huadong Medicine Co., Ltd. (SHE: 000963) announced that the National Medical Products Administration (NMPA) has...
Eli Lilly & Co. (NYSE: LLY) announced first-quarter 2026 global sales of $19.8 billion, representing...
Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) reported first-quarter 2026 total revenues of $99.6 million,...
Viatris Inc. (NASDAQ: VTRS) announced first-quarter 2026 total revenues of $3.5 billion, representing an 8%...
Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a...
Roche AG (SWX: ROP, OTCMKTS: RHHBY) announced a definitive agreement to acquire PathAI, a leading...
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced that the National Medical Products Administration (NMPA)...
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line results from its Phase IIb...
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that its Phase III clinical trial of...
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced successful unblinding of two pivotal Phase III...
Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...